Formulation and In Vitro Characterization of Timolol Maleate Hydrogels: A Review of Strategies Toward Enhanced Ocular Bioavailability

Glaucoma, a leading cause of irreversible blindness worldwide, is primarily managed through pharmacological reduction of intraocular pressure (IOP). Timolol maleate, a non-selective beta-adrenergic blocker, is commonly administered as eye drops; however, conventional formulations are limited by poor ocular bioavailability, rapid precorneal elimination, and patient noncompliance. Recent advances in ocular drug delivery have demonstrated that hydrogel-based systems can improve drug residence time and sustain therapeutic levels. This review summarizes current strategies in formulating Timolol maleate-loaded hydrogels, emphasizing preformulation studies, physicochemical characterization, in vitro release profiles, and ocular compatibility. Key formulation variables such as polymer selection, crosslinking approaches, rheological behaviour, swelling capacity, and drug release kinetics are discussed. In vitro findings consistently demonstrate the potential of hydrogel systems to enhance Timolol retention and prolong drug action without requiring animal experimentation. These results underscore the promise of Timolol maleate hydrogels as a patient-friendly alternative for effective glaucoma management.